Un pas înainte pentru vaccinul împotriva cancerului de piele. Moderna și Merck au anunțat primele rezultate promițătoare

Moderna and Merck announced promising results from a clinical trial of their mRNA-based skin cancer vaccine, showing potential to delay cancer recurrence in high-risk melanoma patients. The study involved 1,137 patients who had undergone surgery for melanoma. The experimental vaccine, Intismeran, was used alongside Merck's Keytruda immunotherapy. This marks a significant advancement in cancer research, as personalized mRNA treatments have long been a goal. Further studies will assess overall survival rates and results will be shared at an upcoming medical conference.